Palliative care and hospice opioid dosing guidelines with breakthrough pain (BP) doses

Abstract

Get full access to this article

View all access options for this article.

References

Lipman AG : Clinically relevant differences among the opioid analgesics. American Journal of Hospital Pharmacy. 1990; 47(58): S7-S13.

Ross FB , Smith MT : The intrinsic anti-nociceptive effects of oxycodone appear to be kappa opioid receptor mediated. Pain. 1997; 73: 151-157.

Ross FB , Wallis SC , Smith MT : Co-administration of sub-antinociceptive doses of oxycodone and morphine produces marked antinociceptive synergy with reduced CNS side-effects in rats. Pain. 2000; 84: 421-428.

Coyle N , Adelhardt J , Foley KM , Portenoy RK : Character of terminal illness in the advanced cancer patient: pain and other symptoms during the last four weeks of life. Journal of Pain and Symptom Management. 1990; 5(2): 83-93.

Faisinger R , Bruera E , et al. : Symptom control during the last week of life on a palliative care unit. Journal of Palliative Care. 1991; 7(1): 5-11.

US Department of Health and Human Services . Management of Cancer Pain, Number 9. AHCPR Publication No. 94-0592, March 1994.

Mercadante S : Costs Are a Further Barrier to Cancer Pain Management. Journal of Pain and Symptom Management. 1999;

Portenoy RK , Lesage P : Management of Cancer Pain. Lancet. 1999; 353: 1695-1700.

Heiskanen T , Kalso E : Controlled-release oxycodone and morphine in cancer related pain. Pain. 1997; 73(1): 37-45.

10.

Portenoy RK , Hagen NA : Breakthrough pain: Definition, prevalence and characteristics. Pain. 1990; 41: 273-281.

11.

Simmonds MA : Management of breakthrough pain due to cancer. Oncology. 1999; 13(8): 1103-1108.

12.

Fine PG , Busch MA : Characterization of breakthrough pain by hospice patients and their caregivers. Journal of Pain and Symptom Management. 1998; 16(3): 179-183.

13.

Portenoy RK, Hagen NA: op. cit.

14.

Patt RB , Ellison NM : Breakthrough pain in cancer patients: Characteristics, prevalence and treatment. Oncology. 1998; 12(7): 1035-1046.

15.

Cherny N , Portenoy RK : Cancer pain management. Cancer. 1993; 72: 3393-3415.

16.

Glare PA , Walsh TD : Dose-ranging study of oxycodone for chronic pain in advanced cancer. Journal of Clinical Oncology. 1993; 11(5): 973-978.

17.

Patt RB: op. cit.

18.

Simmonds MA: op. cit.

19.

Portenoy RK : Analgesic Ladder for the Management of Cancer Pain. New York: The McMahon Group, 1995.

20.

World Health Organization . Cancer Pain Relief. Geneva: World Health Organization, 1986.

21.

Cherny NI : Opioid Analgesics: Comparative features and prescribing Guidelines. Drugs. 1996; 51(5): 713-737.

22.

Twycross R , Wilcock A , Thorp S : Palliative Care Formulary. Oxford: Radcliffe Medical Press, 1998.

23.

Ripamonti C , Groff L , Brunelli C , et al. : Switching from morphine to oral methadone in treating cancer pain: What is the equianalgesic dose ratio? Journal of Clinical Oncology. 1998; 16(10): 3216-3221.

24.

Zhukovsky DS , Walsh D , Doona M : The relative potency between high dose oral oxycodone and intravenous morphine: A case illustration. Journal of Pain and Symptom Management. 1999; 18: 53-55.